Afinitor s is currently in clinical trials for prostate cancer and only preliminary information is available. For example, it is in the phase II study: Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer, NCT00976755.
Several studies have been performed and published. A phase II study (Templeton et al., 2011) investigating the activity of everolimus 10mg/daily as first-line treatment found that in 37 enrolled patients, 12 (32%) remained progression-free at 12weeks. Other phase II studies of everolimus, alone or in combination with bicalutamide, bevacizumab, or chemotherapy, as well as trials testing other mTOR inhibitors such as temsirolimus and ridaforolimus, are currently recruiting patients. More studies are awaited.
For Professional version see here